METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for advanced prostate cancer: experimental combo enters human trials
Disease control Recruiting nowThis early-stage study tests a new drug (JNJ-78278343) combined with other treatments for men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose and to monitor side effects. About 300 participants wil…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 03:19 UTC
-
New study tracks safety of prostate cancer drug darolutamide in korean patients
Disease control Recruiting nowThis study is checking the safety of a drug called darolutamide in Korean men with a type of prostate cancer that hasn't spread or has spread but responds to hormone therapy. The drug works by blocking male hormones that help cancer grow. Researchers will track side effects and s…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Disease control
Last updated May 26, 2026 02:48 UTC
-
New combo aims to shrink prostate cancer tumors faster
Disease control Recruiting nowThis study tests whether adding a new drug (JSB462) to standard hormone therapy (abiraterone) can better control metastatic hormone-sensitive prostate cancer. About 150 men with high-volume disease will receive either the combination or another standard treatment. The goal is to …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 02:47 UTC
-
New shot could replace daily pills for prostate cancer patients
Disease control Recruiting nowThis study tests a new injectable drug, ASP5541, for men with advanced prostate cancer that has spread. The drug is a different form of the standard treatment abiraterone, given as a shot every 12 weeks instead of daily pills. The study will compare how well the injection works a…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 22, 2026 14:05 UTC
-
New prostate cancer drug trial opens for chinese men
Disease control Recruiting nowThis early-stage study tests a new drug called ASP5541 in about 12 Chinese men whose prostate cancer has spread. The drug is given as a shot in the hip, along with standard treatments (prednisone and hormone therapy). The main goals are to check the drug's safety and how it moves…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New radiation therapy aims to shrink tough prostate cancers
Disease control Recruiting nowThis study is for people with metastatic prostate cancer that has spread and is no longer controlled by hormone therapy. It tests a new drug called [212Pb]Pb-ADVC001, which delivers a precise dose of radiation directly to cancer cells. The goal is to find the safest and most effe…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: AdvanCell Pty Limited • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Real-World study tracks darolutamide use in advanced prostate cancer
Knowledge-focused Recruiting nowThis study reviews medical records of 1,400 men with metastatic hormone-sensitive prostate cancer (mHSPC) to see how darolutamide is used in everyday urology clinics. It compares two treatment approaches: darolutamide plus hormone therapy alone (doublet) or with chemotherapy (tri…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated May 26, 2026 03:10 UTC
-
Prostate cancer Pill-Taking habits under the microscope
Knowledge-focused Recruiting nowThis study watches how closely men with advanced prostate cancer follow their prescribed apalutamide treatment over one year. Researchers will track medication adherence and look for patterns that might predict who struggles to stay on track. The goal is to understand real-world …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: Janssen Cilag S.A.S. • Aim: Knowledge-focused
Last updated May 22, 2026 14:03 UTC